iXensor Co., LTD.
TAIPEI, Taiwan and NAIROBI, Kenya , March 16, 2021 (GLOBE NEWSWIRE) -- iXensor Co., Ltd. (6734.TWO)
iXensor, the pioneer of mobile health, partners with Ilara Health, the health-tech company, to solve the lack of affordable medical testing for non-communicable diseases in Kenya's primary care settings by providing integrated point-of-care diagnostics to more than a hundred of small clinics.
"There is an acute need in Kenya and across the continent for early detection of metabolic diseases. With iXensor's PixoTest, our partner facilities can do this. The PixoTest POCT System is affordable, portable, and its data integration feature allows us to use it for remote patient management, ensuring that patients can receive the highest quality of care when managing their conditions," said Mr. Emilian Popa, the CEO of Ilara Health.
More than 70% of the patients seeking medical care from small clinics require testing, and they are usually referred to larger centralized clinical centers. However, the time and cost of visiting large medical centers are enormous barriers to the majority.
By connecting iXensor’s palm-size PixoTest diagnostics to Ilara Health's Mbali Health platform, the two startups provide rapid blood testing and digital communication services to patients directly through clinics. Dr. Mwihurih Githinji commented, "Because of lifestyle changes, NCDs are becoming bigger healthcare burdens with diabetes and hypertension taking the lead. If I am able to identify diabetes or pre-diabetics earlier, then the management will be much faster."
Dr. Carson Chen, the CEO of iXensor addressed that "Being able to communicate the blood test results directly through patients’ mobile phones is a great benefit we are empowering the healthcare professionals on the front line. Together with Ilara Health, we will continue to expand the access to timely and quality medical testing for more patients in need of better care."
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical diagnostics across infectious diseases, women's health, and cardiovascular diseases.
Media Contact
Spokesperson: Patrick Liao
Company Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-2-8751-1335 ext.205
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7fd3198-7a7b-4a9c-88eb-f3e27dd94060
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Atico Mining Corporation30.6.2025 22:29:54 CEST | Press release
Atico Mining Announces Execution of Loan Amendment with Trafigura to Restructure Outstanding Credit Facility
Top California Lender30.6.2025 22:02:33 CEST | Press release
Top California Lender Welcomes New Investors to Fuel Expanded Lending Capacity
Ress Life Investments A/S30.6.2025 20:20:00 CEST | Press release
Ress Life Investments A/S publishes Net Asset Value (NAV).
Barclays Bank PLC30.6.2025 19:35:11 CEST | Press release
Barclays Bank PLC: Launch of accelerated placing of shares in InPost
Novonesis (Novozymes A/S)30.6.2025 18:59:15 CEST | Press release
Transactions under Novonesis’ share buyback program
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom